Hemab Therapeutics
PublicHemab Therapeutics is now publicly traded
The data on this page reflects Hemab Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
May 1, 2026
Last Round
Series C
Oct 27, 2025
Total Funding Raised
$853.66M
Company Overview
Hemab Therapeutics is a biotechnology company that develops prophylactic therapeutics aimed at treating bleeding and thrombosis disorders by enhancing the body's natural clotting mechanisms to prevent life-threatening complications.
Sector
Biotech
Verticals
Digital Health, HealthTech, Life Sciences
AI Layer
Non-AI
Keywords
Hemab Therapeutics Comparables
Compare Hemab Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Eli Lilly and Company | 77% | |
| Incyte Corporation | 76% | |
| Novo Nordisk | 72% | |
Hemab Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | May 1, 2026 | ||||
| Series C | Oct 27, 2025 | ||||
| Series C | Oct 27, 2023 | ||||
| Series B | Feb 16, 2023 | ||||
| Series A | Jul 22, 2021 | ||||
Seed | Dec 14, 2020 |
Key People
Founding team and executive leadership
Hemab Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | IPO |
| Access Industries | Series B |
| Evercore ISI | IPO |
| Maj Invest Equity A/S | Series B, Series C |
| RA Capital Management | Series C, Series B, Series A |
| Avoro Ventures | Series C, Series B |
| Avoro Capital | Series B |
Hemab Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
